☰

Fatima Rangwala, Ph.D. - Publications

Affiliations: 
University of Cincinnati, Cincinnati, OH 
Area:
Schwann cell development
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

4/30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lyerly HK, Diehl AM, Morse MA, Devi GR. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. Bmc Cancer. 12: 402. PMID 22963400 DOI: 10.1186/1471-2407-12-402  0.372
2006 Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Research. 66: 2584-91. PMID 16510576 DOI: 10.1158/0008-5472.Can-05-3330  0.43
2006 Mahller YY, Rangwala F, Ratner N, Cripe TP. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatric Blood & Cancer. 46: 745-54. PMID 16124003 DOI: 10.1002/Pbc.20565  0.471
2004 Huang Y, Rangwala F, Fulkerson PC, Ling B, Reed E, Cox AD, Kamholz J, Ratner N. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene. 23: 368-78. PMID 14724565 DOI: 10.1038/Sj.Onc.1207075  0.419
Low-probability matches (unlikely to be authored by this person)
2014 O'Reilly EM, Smith LS, Bendell JC, Rangwala FA, Schmidt W, Stephenson J, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Cohn AL. Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). Journal of Clinical Oncology. 32: 220-220. DOI: 10.1200/jco.2014.32.3_suppl.220  0.259
2011 Rangwala F, Omenetti A, Diehl AM. Cancer stem cells: repair gone awry? Journal of Oncology. 2011: 465343. PMID 21188169 DOI: 10.1155/2011/465343  0.231
2016 Subbiah V, Bang Y, Lassen UN, Wainberg ZA, Soria J, Wen PY, Zenz T, Moreau P, Brunsvig P, De Braud FG, De Greve J, De Jonge MJ, Hofheinz RD, Italiano A, Stein A, ... ... Rangwala FA, et al. ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy. Journal of Clinical Oncology. 34: TPS2604-TPS2604. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2604  0.216
2018 Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, ... ... Rangwala F, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discovery. PMID 29431699 DOI: 10.1158/2159-8290.Cd-17-1226  0.179
2012 Rangwala FA, Bendell JC, Kozloff M, Arrowood C, Meadows J, Tourt-Uhlig SE, Murphy J, Meadows K, Morse M, Uronis HE, Hsu SD, Zafar Y, Hurwitz H. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 490. PMID 27983003 DOI: 10.1200/jco.2012.30.4_suppl.490  0.178
2022 Yoo KJ, Johannes K, González LE, Patel A, Shuptrine CW, Opheim Z, Lenz K, Campbell K, Nguyen TA, Miriyala J, Smith C, McGuire A, Tsai YH, Rangwala F, de Silva S, et al. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade. Journal of Immunology (Baltimore, Md. : 1950). PMID 35817517 DOI: 10.4049/jimmunol.2101175  0.178
2014 Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, et al. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational New Drugs. 32: 700-9. PMID 24711126 DOI: 10.1007/s10637-014-0089-2  0.164
2016 Corcoran R, André T, Yoshino T, Bendell J, Atreya C, Schellens J, Ducreux M, McRee A, Siena S, Middleton G, Gordon M, Humblet Y, Muro K, Elez E, Yaeger R, ... ... Rangwala F, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 27: vi150. DOI: 10.1093/Annonc/Mdw370.04  0.163
2011 Rangwala F, Guy CD, Lu J, Suzuki A, Burchette JL, Abdelmalek MF, Chen W, Diehl AM. Increased production of sonic hedgehog by ballooned hepatocytes. The Journal of Pathology. 224: 401-10. PMID 21547909 DOI: 10.1002/Path.2888  0.162
2015 Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, McRee AJ, O'Dwyer PJ, Muro K, Tabernero J, van Geel R, Sidhu R, Greger JG, Rangwala FA, Motwani M, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: 103-103. DOI: 10.1200/Jco.2015.33.15_Suppl.103  0.151
2018 Kreitman RJ, Moreau P, Hutchings M, Gazzah A, Blay J, Wainberg ZA, Stein A, Dietrich S, de Jonge MJ, Willenbacher W, De Greve J, Arons E, Ravandi F, Rangwala F, Burgess P, et al. Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL) Blood. 132: 391-391. DOI: 10.1182/blood-2018-99-113135  0.151
2017 Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JH, Soria J, Wen PY, Zielinski C, Urbanowitz G, Mookerjee B, Wang D, Rangwala FA, Keam B. Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC). Journal of Clinical Oncology. 35: 6023-6023. DOI: 10.1200/Jco.2017.35.15_Suppl.6023  0.147
2017 Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017736785. PMID 29072975 DOI: 10.1200/Jco.2017.73.6785  0.146
2020 Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, ... ... Rangwala F, et al. BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32047001 DOI: 10.1158/1078-0432.Ccr-19-3579  0.137
2014 Clarke JM, Hurwitz HI, Rangwala F. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. Cancer Treatment Reviews. 40: 1065-72. PMID 25047778 DOI: 10.1016/j.ctrv.2014.07.001  0.129
2015 Van Cutsem E, Atreya C, André T, Bendell J, Schellens J, Gordon M, McRee A, Yoshino T, Muro K, ODwyer P, Tabernero J, Middleton G, Ducreux M, van Geel R, Sidhu R, ... ... Rangwala F, et al. LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 26: iv119. DOI: 10.1093/Annonc/Mdv262.07  0.117
1997 Rangwala F, Drisdel RC, Rakhilin S, Ko E, Atluri P, Harkins AB, Fox AP, Salman SS, Green WN. Neuronal alpha-bungarotoxin receptors differ structurally from other nicotinic acetylcholine receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 8201-12. PMID 9334396 DOI: 10.1523/Jneurosci.17-21-08201.1997  0.108
2016 Strickler JH, Rangwala FA, Rushing C, Niedzwiecki D, Altomare I, Uronis HE, Hsu SD, Zafar Y, Morse M, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Webb AR, Dropkin E, et al. X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 34: 687-687. DOI: 10.1200/jco.2016.34.4_suppl.687  0.09
2018 Wen P, Alexander S, Yung-Jue B, van den Bent M, Gazzah A, Dietrich S, de Vos F, van Linde M, Lai A, Chi A, Prager G, Campone M, von Bubnoff N, Fasolo A, Lopez-Martin J, ... ... Rangwala F, et al. RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) Neuro-Oncology. 20: vi238-vi238. DOI: 10.1093/neuonc/noy148.986  0.083
2019 Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, ... ... Rangwala FA, et al. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. Bmc Cancer. 19: 1032. PMID 31675952 DOI: 10.1186/s12885-019-6234-8  0.073
2018 Keam B, Kreitman RJ, Wainberg ZA, Cabanillas ME, Cho DC, Italiano A, Stein A, Cho JY, Schellens JHM, Wen PY, Zielinski CC, Boran AD, Mookerjee B, Burgess P, Rangwala F, et al. Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii645-viii646. PMID 32137753 DOI: 10.1093/Annonc/Mdy302.002  0.071
2018 Spiegel D, Boyer M, Hong JC, Williams CD, Kelley MJ, Rangwala FA, Salama JK, Palta M. Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis. Journal of Clinical Oncology. 36: 741-741. DOI: 10.1200/JCO.2018.36.4_suppl.741  0.066
2012 Rangwala F, Zafar SY, Abernethy AP. Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach. Current Opinion in Supportive and Palliative Care. 6: 69-76. PMID 22228030 DOI: 10.1097/SPC.0b013e32834f689d  0.059
2012 Prada CE, Rangwala FA, Martin LJ, Lovell AM, Saal HM, Schorry EK, Hopkin RJ. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. The Journal of Pediatrics. 160: 461-7. PMID 21996156 DOI: 10.1016/j.jpeds.2011.08.051  0.054
2011 Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, Moylan C, Venkatraman T, Feuerlein S, Syn WK, Jung Y, Witek RP, Choi S, Michelotti GA, Rangwala F, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. Plos One. 6: e23943. PMID 21912653 DOI: 10.1371/Journal.Pone.0023943  0.047
2012 Rangwala F, Putcharoen O, Bowonwatanuwong C, Edwards-Jackson N, Kramomthong S, Kim JH, Corey GR, Ananworanich J. Histoplasmosis and penicilliosis among HIV-infected Thai patients: a retrospective review. The Southeast Asian Journal of Tropical Medicine and Public Health. 43: 436-41. PMID 23082594  0.041
Hide low-probability matches.